ENDRA Life Sciences Inc Dossier
Qualitative Analysis
Business overview
ENDRA Life Sciences Inc. is a medical technology company pioneering Thermo Acoustic Enhanced UltraSound (TAEUS®), a proprietary platform technology designed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures at the point of patient care. The company's primary clinical focus is on the non-invasive measurement of liver fat to aid in the early detection, diagnosis, and monitoring of Steatotic Liver Disease (SLD), formerly known as fatty liver disease, and Metabolic Dysfunction-Associated Steatohepatitis (MASH). By enhancing the capabilities of existing clinical ultrasound systems, TAEUS® aims to provide a cost-effective, point-of-care alternative to the clinical gold standard, Magnetic Resonance Proton Density Fat Fraction (MRI-PDFF), which is highly accurate but expensive and difficult to scale.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
The Board of Directors initiated a formal process to explore strategic alternatives, including strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.
Expected impact: Aims to maximize shareholder value and secure a sustainable corporate structure or exit path.
Implementation of a capital management strategy to optimize capital preservation and generate non-dilutive returns by investing a portion of corporate treasury into decentralized finance (DeFi) assets, specifically staking HYPE tokens (the native token of the Hyperliquid ecosystem).
Expected impact: Designed to generate consistent, non-dilutive financial returns, enhance balance sheet flexibility, and provide supplemental financial resources to support core operations.
Focusing on validating the clinical accuracy, repeatability, and reproducibility of the TAEUS Liver system against the gold-standard MRI-PDFF through multi-site clinical studies and partnerships with prestigious institutions.
Expected impact: Establishes clinical proof-of-concept and generates the necessary data to support FDA De Novo regulatory clearance and commercial adoption.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
King's College Hospital in London is utilizing the TAEUS liver system in a clinical study of approximately 75 subjects to compare its liver fat assessment accuracy against MRI, providing critical peer-reviewed clinical evidence for European and global markets.
Terms: Not publicly disclosed.
Arca guides ENDRA's Digital Asset Treasury strategy, combining crypto-native expertise with traditional risk management to select and manage high-conviction DeFi holdings.
Terms: Annual management fee ranging from 1.25% to 1.75% of assets under management, plus a 10% to 15% performance fee.
Provides secure, institutional-grade custody and staking services for ENDRA's HYPE token holdings to support its Digital Asset Treasury strategy.
Terms: Not publicly disclosed.